Evidence map›Paper›PMID 19904585›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2009

D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

Leonid A Khinkis, Wojciech Krzyzanski, William J Jusko, William R Greco

Abstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. D optimal designs for three Poisson dose-response models.Journal of pharmacokinetics and pharmacodynamics · 2013
    Article
  3. Lifespan based indirect response models.Journal of pharmacokinetics and pharmacodynamics · 2012
    Review
  4. Article
  5. An example of optimal phase II design for exposure response modelling.Journal of pharmacokinetics and pharmacodynamics · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leonid A KhinkisDepartment of Mathematics and Statistics, Canisius College, 2001 Main Street, Buffalo, NY 14208-1098, USA.
Wojciech Krzyzanski
William J Jusko
William R Greco

Funding

MATHEMATICAL MODELS IN PHARMACODYNAMICSR01GM057980 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JUSKO, WILLIAM J., KRZYZANSKI, WOJCIECH · 1998 to 2013
$3.4M
Concentration-time-effect modeling of agent combinationsR01RR010742 · NCRR · ROSWELL PARK CANCER INSTITUTE CORP · PI GRECO, WILLIAM ROBERT · 1994 to 2006
$1.2M
NCRR NIH HHS R01 RR010742NCRR NIH HHS RR10742NIGMS NIH HHS GM57980NIGMS NIH HHS R01 GM057980
6 · The paper itself

Abstract

This report generates efficient experimental designs (dose, sampling times) for parameter estimation for four basic physiologic indirect pharmacodynamic response (IDR) models. The principles underlying IDR models and their response patterns have been well described. Each IDR model explicitly contains four parameters, k (in) (production), k (out) (loss), I (max)/S (max) (capacity) and IC (50)/SC (50) (sensitivity). The pharmacokinetics of an IV dose of drug described by a monoexponential function of time with two parameters, V and k (el), is assumed. The random errors in the response variable are assumed to be additive, independent, and normal with zero mean and variance proportional to some power of the mean response. Optimal design theory was used extensively to assess the role of both dose and sampling times. Our designs were generated in Mathematica (ADAPT 5 typically produces identical results). G-optimality was used to verify that the generated designs were indeed D-optimal. Such designs are efficient and robust when good prior knowledge of the estimated parameters is available. The efficiency of unconstrained D-optimal designs (4 dose, sampling time pairs) does not improve much when the drug doses are allowed to differ, compared with constrained single dose designs (4 sampling times) with one maximal feasible dose. Also, explored were efficiencies of alternative study designs and results from parameter misspecification. This analysis substantiates the importance of larger doses yielding greater certainty in parameter estimation in pharmacodynamics.

Indexed as

Models, BiologicalPharmacokineticsPharmacologyAnimalsComputer SimulationDose-Response Relationship, DrugDrug Dosage CalculationsHumansSoftware

Identifiers

PMID19904585
PMCPMC3752677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.